Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer

Eur J Cancer. 2024 Sep:208:114193. doi: 10.1016/j.ejca.2024.114193. Epub 2024 Jun 27.

Authors

Léa Mercier¹, Matthieu Delaye², Alina Fuerea², Michel Ducreux³, Alice Boilève³

Affiliations

¹ Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France. Electronic address: [email protected].
² Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France.
³ Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France; Université Paris Saclay, 91400 Orsay, France.

PMID: 38996797
DOI: 10.1016/j.ejca.2024.114193

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Administration, Oral
Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cetuximab* / administration & dosage
Cetuximab* / adverse effects
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
Humans
Intestinal Obstruction / etiology

Substances

Cetuximab